Truist Financial Corp Sells 17,873 Shares of Hologic, Inc. (NASDAQ:HOLX)

Truist Financial Corp cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 13.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 119,050 shares of the medical equipment provider’s stock after selling 17,873 shares during the quarter. Truist Financial Corp owned 0.05% of Hologic worth $8,839,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Massmutual Trust Co. FSB ADV increased its stake in Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares in the last quarter. Graypoint LLC increased its position in shares of Hologic by 3.9% during the first quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock worth $302,000 after acquiring an additional 147 shares in the last quarter. Sequoia Financial Advisors LLC raised its stake in shares of Hologic by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock worth $536,000 after purchasing an additional 165 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in Hologic by 0.6% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 31,112 shares of the medical equipment provider’s stock valued at $2,425,000 after acquiring an additional 192 shares in the last quarter. Finally, Curbstone Financial Management Corp boosted its holdings in Hologic by 0.9% during the 2nd quarter. Curbstone Financial Management Corp now owns 23,126 shares of the medical equipment provider’s stock worth $1,717,000 after acquiring an additional 200 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

Shares of HOLX opened at $80.24 on Friday. The stock has a 50-day moving average price of $81.28 and a 200-day moving average price of $77.42. The company has a market cap of $18.73 billion, a PE ratio of 40.94, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the business posted $0.93 earnings per share. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, equities analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, September 17th. Evercore ISI boosted their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and cut their price target for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and an average target price of $87.27.

Insiders Place Their Bets

In other news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now directly owns 45,472 shares in the company, valued at $3,615,024. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock valued at $1,469,973 over the last quarter. 1.75% of the stock is owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.